Clene Inc. · NASDAQ:CLNN
Clene — Technical Presentation (February 2021)
11 slides from Clene's technical presentation, Feb 26, 2021
Slide 1: Update to a Phase 2 trial of CNM-Au8 for chronic optic neuropathy
Robert Glanzman, MD FAAN For the VISIONARY - MS Investigators R . G l a n z m a n , M D F AA N 1 , H . Bea d n a l l MBBS F R A C P 2 , A . Klistorner , M. Barnett, MBBS FRACP 2 , R. Sergott MD 3 , A. Rynders 1 , K. Ho, PhD 1 , M. Mortenson MS 1, M. Hotchkin 1 1 Holladay, UT/United States, 2 Camperd
Slide 2: Disclosures and Acknowledgements
Disclosures I a m a n e m p l o y e e o f C l en e N a n o m e d i c i n e , I n c . and receive salary and stock options Acknowledgements Dr. Heidi Beadnall MBBS, FRACP Dr. Steve Vucic MBBS FRACP, PhD Prof Neurology Dr. Jeanette Lerchner - Scott MD, PhD, FRACP Dr. Stefan Blum MD, FRACP, PhD Dr. Bru
Slide 3: CNM-Au8 MoA: Nanocatalytic Electron Transfer
C N M - Au8 | M o A : N a n o c a t a l y t i c E l e c t r o n T r a n s f e r 3
Slide 4: Background DMT Treatment & Demographics - January 2021
Background DMT Treatment & Demographics 1 3 - J a nu a r y - 2021 B li n d e d D a ta U pd a te 4 B as e li ne Values Sub j e ct s n (%) Age [ y r s . ] mean (SD) EDSS m ea n (SD) Time from MS Onset [yrs.] m ea n ( SD ) ON History [%] All 52 38.0 1.8 6.0 76% (100%) (8.9) (1.5) (3.8) Female 37 37.7 1
Slide 5: Treatment of Visual Pathway Deficits in Chronic Optic Neuropathy
5 Treatment of Vis ual Pathway Deficits I n Chronic O ptic N europathy for A ssessment of R em y elination in Non - Active Relapsing MS Change in Low Contrast Letter Acuity (LCLA) At Week 24 Up to 48 - Week Placebo - Control 2:1 Randomization (Active: Placebo ) 1 5 m g , 3 0 m g , P l a c e b o (n =
Slide 6: SDMT Z-Score Change
( T L T V + E = 1 2 3 4 5 6 7 8 9 KEY SDMT Z - Score Change Change in Enrolled Study Population Compared to Baseline (BL) ‘Mild’ EDSS (<=1.5) 6
Slide 7: 9HPT (Non-Dominant) Z-Score Change
9HPT (Non - Dominant) Z - Score Change Change in Enrolled Study Population Compared to Baseline (BL) ‘Mild’ EDSS (<=1.5) 7
Slide 8: T25FW Z-Score Change
T25FW Z - Score Change Change in Enrolled Study Population Compared to Baseline (BL) ‘Mild’ EDSS (<=1.5) 8
Slide 9: LCLA (Best-Corrected) Z-Score Change
LCLA (Best - Corrected) Z - Score Change Change in Enrolled Study Population Compared to Baseline (BL) ‘Mild’ EDSS (<=1.5) 9
Slide 10: (m)MSFC Mean Z-Score Change
(m)MSFC Mean Z - Score Change 6 - component (SDMT, LCLA [L/R], 9HPT [D/ND], T25FW) ( T L T V + E = 1 2 3 4 5 6 7 8 9 KEY 10
Slide 11: Conclusions
Conclusions • These interim, blinded data support the potential for CNM - Au8 therapy to demonstrate meaningful neurological improvement in patients with MS • VISIONARY - MS is an innovative Phase 2 study examining the potential for CNM - Au8 to promote neurological improvement in a stable RMS popul